Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Teva
US Army
Colorcon
Express Scripts
Citi
Dow
Baxter
Queensland Health
McKinsey

Generated: January 23, 2018

DrugPatentWatch Database Preview

OFIRMEV Drug Profile

« Back to Dashboard

Which patents cover Ofirmev, and when can generic versions of Ofirmev launch?

Ofirmev is a drug marketed by Mallinckrodt Ip and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-nine patent family members in twenty-six countries.

The generic ingredient in OFIRMEV is acetaminophen. There are sixty-six drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the acetaminophen profile page.
Drug patent expirations by year for OFIRMEV
Medical Subject Heading (MeSH) Categories for OFIRMEV

US Patents and Regulatory Information for OFIRMEV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mallinckrodt Ip OFIRMEV acetaminophen SOLUTION;IV (INFUSION) 022450-001 Nov 2, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for OFIRMEV
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 1000 mg/100 mL (10 mg/mL) ➤ Subscribe 4/7/2011

International Patents for OFIRMEV

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Teva
Boehringer Ingelheim
Cipla
Express Scripts
QuintilesIMS
Moodys
Julphar
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot